Sino Biopharmaceutical Limited has announced promising data from a Phase II clinical study of TQB2868, a PD-1/TGF-β bi-functional fusion protein, combined with anlotinib and chemotherapy as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the study enrolled 40 stage IV mPDAC patients, with 36 being evaluable. The preliminary results demonstrated robust efficacy, marking a significant breakthrough in addressing the treatment challenges of pancreatic cancer, known for its high malignancy and low survival rate. The company is currently in discussions with China's National Medical Products Administration to advance to Phase III trials, with the potential for TQB2868 to become the first immune checkpoint inhibitor as a first-line treatment option.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。